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Drug-induced interstitial pneumonia is a severe disease that has been reportedly caused by more than
100 compounds, the most common being amiodarone, methotrexate and bleomycin. We report a case of
fatal acute interstitial pneumonia occurring after a second injection of 131I-labeled lipiodol for hepato-
cellular carcinoma treatment. Infectious pneumonia was ruled out and lung biopsy revealed a pattern of
usual interstitial pneumonia. Despite early initiation of systemic corticosteroids and additionally, anti-
oxidant medications, the patient’s condition gradually worsened and he died 24 days after admission.
131I-labeled lipiodol-induced interstitial pneumonia is probably frequently undiagnosed. A better
knowledge of this disease would help to estimate its true incidence and may impact on the perceived
risk/beneﬁt ratio for its treatment. Moreover, this may have consequences on the prescription of 131I-
labeled lipiodol.
 2010 Elsevier Ltd. All rights reserved.Drug-induced interstitial pneumonia is a severe disease that has
been reportedly caused by more than 100 compounds (e.g. amio-
darone, methotrexate and bleomycin). We report a case of fatal
acute interstitial pneumonia following a 131I-labeled lipiodol
injection for hepatocellular carcinoma treatment.
In 2009, a 62-year-old man, with no history of smoking, was
admitted for rapidly increasing shortness of breath. His past
medical history was unremarkable including arterial hypertension
treated with irbesartan and hydrochlorothiazide.
Eighteen months prior to admission, he was diagnosed with
alcohol related liver cirrhosis (Child-Pugh grade A5) and a multi-
focal hepatocellular carcinoma, as shown by CT-scan. The serum
alpha-feto-protein (AFP) level was 12,860 ng/mL (normal value
<10 ng/mL). The patient was treated with doxorubicin, via intra-
arterial chemotherapy. Portal vein thrombosis was discovered
during an arterial opaciﬁcation procedure, which contra-indicated
the arterial embolisation that was initially planned to complete
treatment for the carcinoma. The tolerance for this procedure was
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rved.Seven months prior to admission, the patient received his ﬁrst
intra-arterial injection, of 131I-labeled lipiodol (60 mCi), in situ.
Again, the tolerance for this procedure was rated as excellent.
Thoraco-abdominal scintigraphy performed 7 days after this ﬁrst
injection revealed limited lung ﬁxation.
Four months prior to admission, a thoraco-abdominal CT-scan
found no abnormality in the lung parenchyma. The serum AFP level
was 6 ng/mL. The patient received a second injection of 131I-labeled
lipiodol three weeks before admission. The patient had not repor-
ted any complaints during the week following this second injection
while the scintigraphy revealed mild to moderate lung ﬁxation.
Over the two weeks that preceded his admission, the patient
progressively developed a dry cough and shortness of breath. On
admission, the patient was in acute respiratory failure with
a respiratory rate of 35 breaths/min and a pulsed-oxygen saturation
level of 80% when the patient was breathing room air. A physical
examination revealed cyanosis, bilateral crackles and a body
temperature of 38.8 C. Arterial blood gases on oxygen supple-
mentation (8 L/min) were: PaO2 ¼ 87 mmHg, PaCO2 ¼ 37 mmHg. A
chest X-Ray revealed bilateral opacities. Cefotaxime and oﬂoxacine
were initiated on the day of admission (Day 0).
A broncho-alveolar lavage (BAL) was performed on Day 1.
Cytological studies of BAL ﬂuid revealed a cell count of
500,000 cells/mL with 53% lymphocytes (predominantly CD4
positive (73%)), 45% macrophages, 2% neutrophils and 1%
Fig. 1. Chest CT-scan showing diffuse bilateral ground glass opacities (A and B) with retraction of both lower lobes suggestive of ﬁbrosis (B).
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found. Neither was there any detection of bacteria, virus, fungi nor
parasites in the BAL. Urinary and serological testing for pathogens
was negative and no precipitins for allergic alveolar pneumonia
were found. Echocardiography was normal. Intravenous methyl-
prednisolone (1.5 mg/kg/day) was initiated on Day 1. A chest CT-
scan performed on Day 7 revealed diffuse bilateral ground glass
opacities with retraction of both lower lobes suggestive of ﬁbrosis
(Fig. 1). No pulmonary embolism was found. Corticosteroid doses
were increased to 3 mg/kg/day and antioxidant medications were
introduced with tocopherol (500 mg/day) and N-acetyl cystein
(900 mg/day). Tracheal intubation was necessary on Day 14 for
mechanical ventilation, but the patient’s condition gradually
worsened. A videothoracoscopy-assisted lung biopsy was per-
formed on Day 15. All microbiological studies were negative
(bacteriology, virology, mycology and parasitology). The histolog-
ical patterns were indicative of usual interstitial pneumonia. The
patient died of intractable respiratory failure on Day 24.
131I-labeled lipiodol is a viscous contrast product, used as
intratumoral chemotherapy for non-resectable hepatocellular
carcinoma when portal vein thrombosis contraindicates chemo-
embolisation.1,2 This treatment is usually well tolerated.1,2
However, some adverse events reported during the 131I-labeled
lipiodol studies, such as infectious pneumonia or cardiac failure,
could actually be undiagnosed 131I-labeled lipiodol-induced pneu-
monia.3 Indeed, drug-induced pneumonia is not easily differenti-
ated from other causes of lung inﬁltrates, especially when
investigations are limited, which may be the case in patients with
intractable hepatocellular carcinoma.
The lung is the second site of ﬁxation for radioactive lipiodol,
with an uptake of 131I-labeled lipiodol during the ﬁrst and second
treatment of, respectively, 16% and 17% in the lungs, corresponding
to 3 Gy.3 In 2005, the “Agence Française de Sécurité Sanitaire des
Produits de Santé” (AFSSAPS), the French Medicines Agency, issued
a warning after 13 cases of interstitial pneumonia were reported
following 131I-labeled lipiodol administration.4 However, 4 years
on, the scarcity of data on 131I-labeled lipiodol-induced interstitial
pneumonia is striking and suggests that cases of interstitial pneu-
monia following 131I-labeled lipiodol injection may remain
undiagnosed.
The pathophysiology of 131I-labeled lipiodol-induced pneu-
monia is not univocal, an allergic mechanism is possible, but
a radioactive-induced mechanism is supported by many factors.
The fact that these pneumonia have been most frequently reported
after the second 131I-labeled lipiodol injection could indicate that
pre-radiation sensitisation is a necessary step in this disease’s
process.5 Clinical and radiological features ﬁt with the usual char-
acteristics of radiation pneumonitis.5 Moreover, the radiation dosedelivered in the lungs during each 131I-lipiodol injection is 3 Gy and
it has been shown that a radiation dose per fraction greater than
2.67 Gy is signiﬁcantly associated with the risk of radiation
pneumonitis.6,7
Beside corticosteroids, antioxidant therapies could theoretically
be of value given the suspected pathophysiology. In a mousemodel,
over-expression of manganese superoxide dismutase has been
shown to protect against acute and chronic radiation pneumonitis.8
In the observation reported herein, antioxidant drugs (tocopherol
and N-acetyl cystein) were initated early (Day 7), in addition to
high-dose corticosteroids, but no signiﬁcant effect was observed
throughout the hospitalization. Other drugs may be of interest in
this setting e Imatinib had beneﬁcial effects in a mouse model of
radiation pneumonitis.8 Cyclosporin A or pentoxifylline combined
with tocopherol may be of value but their actions are delayed.9,10
In conclusion, 131I-labeled lipiodol-induced interstitial pneu-
monia is a severe disease that may be frequently undiagnosed.
Better knowledge of this disease’s pathophysiology, incidence and
clinical characteristics is necessary to better assess the risk/beneﬁt
ratio of 131I-labeled lipiodol use in hepatocellular carcinoma
treatment, especially when curative treatment such as liver trans-
plantation or surgical resection are alternative options.Acknowledgments
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